Overview

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Active, not recruiting
Trial end date:
2021-11-02
Target enrollment:
Participant gender:
Summary
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Adavosertib
Carboplatin
Gemcitabine
Paclitaxel